iPS-CAR-Mac03

N/A

Report date: 2025/03/20 16:04:40

Base Information

Drug NameiPS-CAR-Mac03
Drug Alias Nameallogeneic iPSC-derived CAR-iMac cell therapy (Cellorigin Biotech/Qilu Pharma/Zhejiang University)CAR-iMAC Cell Therapy (CellOrigin Biotech/Qilu Pharma/Zhejiang University)
ClassificationBiologicsCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapy
Mechanisms of ActionImmunostimulantsMacrophages stimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesCellOrigin Technology (Hangzhou) Co LtdQilu Pharmaceutical Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A